KORRO BIO, INC. (KRRO) Reports the reporting period Financial Results
KORRO BIO, INC. (KRRO) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 2550
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 157053
Hosted Analyst Day showcasing KRRO
121’s potential to treat hyperammonemia in patients with UCDs and HEoForum featured Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a UCD and UCD patient advocate. oFocused on profiling the unmet need in serving both patient populations afflicted with hyperammonemia, and KRRO
📋 KORRO BIO, INC. (KRRO) - Financial Results
Filing Date: 2026-05-07
Accepted: 2026-05-07 07:04:16
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: